2019 report now available
Corporate reputation of Pharma 2019
From the patient perspective 2019-2020
From 1st November 2019 to 26th February 2020, PatientView asked patient groups around the world to comment on the reputation of the pharmaceutical industry and individual companies within it.
The survey was conducted in 20 languages:
Danish | Dutch | English | Finnish | French | German | Greek | Hungarian | Italian | Japanese | Korean | Norwegian | Portuguese | Polish | Russian | Spanish | Swedish | Simplified Chinese | Traditional Chinese | Turkish.
Companies included in the 2020 publications of the corporate reputation survey:
AbbVie I Acorda Therapeutics I Allergan I Almirall I Amgen I Astellas Pharma I AstraZeneca I Bayer I Bial I Biogen I Boehringer Ingelheim I Bristol-Myers Squibb I Celgene I Chiesi Farmaceutici I CSL Behring I Daiichi Sankyo I Eisai I Eli Lilly (Lilly) I Ferring I Gedeon Richter I Gilead/Kite Pharma I Grifols I Grünenthal I GSK I Ipsen I Janssen I LEO Pharma I Lundbeck I Menarini I Merck & Co (MSD outside of the US) I Merck KGaA/EMD Group I Novartis I Novo Nordisk I Octapharma I Otsuka I Pfizer I Pierre Fabre Laboratories I Roche (Genentech in the US, Chugai in Japan) I Sanofi I Servier I Takeda (including Shire) I Teva I UCB I Vertex Pharmaceuticals I Vifor I ViiV Healthcare
Industry and companies were assessed for their performance at 12 indicators from the perspective of patient groups:
- Patient centricity
- Quality of patient information
- Safety provided to patients
- Usefulness and benefits of products to patients
- Transparency (clinical data, funding of external stakeholders, pricing policies)
- Provision of services ‘beyond the pill’
- The quality of patient-group partnerships;
- Patient engagement in R&D.
The first data analysis in April 2020 looked at pharma reputation from a global viewpoint.
Other analyses produced during the year include:
Therapy areas: Autoimmune | Bleeding disorders (published)| Cancer (published) | HIV/AIDS (published) | Mental health | Neurological | Rare diseases | and Respiratory (published) [8datasets/reports].
Geographic areas: global (pubnlished) Canada (published)| Germany | Italy (published) | Asia | Spain | the UK (published) | and the USA (published) [8 datasets /reports].